An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus.
Phase of Trial: Phase II
Latest Information Update: 08 May 2019
At a glance
- Drugs Solcitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 08 May 2019 This trial is completed in Estonia according to European Clinical Trials Database record.
- 31 Aug 2018 Biomarkers information updated
- 01 Nov 2016 Results published in the Lupus